First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 220 participants.

Also called NCT05939076

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 220 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05939076
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Hungary, Slovakia, Sweden, United Kingdom (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT05939076. Randomized; quadruple masking; primary purpose treatment. Start 2023-08-21 (anticipated); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation
Condition
Atrial Fibrillation, Persistent
Intervention (Device)
Pulmonary vein isolation
Intervention (Drug)
dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™
Lead sponsor
Region Örebro County (class: other)
Collaborator
The Swedish Research Council (class: other government)
Collaborator
Erling-Persson Stiftelse (class: not stated)
Collaborator
Swedish Heart Lung Foundation (class: other)
Collaborator
Uppsala University (class: other)

Record details

Record id
cardio:ct-nct05939076
Content hash
daeb120330f375def8370edf73062dce05f9b128b057dc21f38a0cf35ede5dc8